Medical AI company
Bayesian Health
Clinical AI platform that continuously monitors inpatients and alerts clinicians to risks such as sepsis, with FDA-cleared sepsis monitoring.
Company overview
Bayesian Health provides a real-time clinical intelligence platform that reads the full patient chart, monitors patients continuously and surfaces those who need attention along with guidance for clinicians. The company announced FDA clearance for continuous AI sepsis monitoring. It was founded by machine learning researcher Dr. Suchi Saria.
- Headquarters
- United States
- Company type
- AI Technology Developer, Healthcare IT Provider
In its own words: “Bayesian monitors every patient continuously, surfaces only those who need attention, and gives clinicians the guidance to act, consistently, at scale.” source
AI products and platforms
- Bayesian real-time clinical intelligence platformAI-powered
Continuous AI patient monitoring with risk alerts and clinical guidance, including sepsis.
Product page ↗
Technology categories
Clinical applications
- inpatient deterioration and sepsis detection
- clinical alerting
Markets served
- United States
Regulatory information
- FDA clearance for continuous AI sepsis monitoring (company announcement) source
As stated by the company or the cited regulator page. Authorisation is specific to a product, version and market; confirm the current status with the company and the regulator. About medical device regulation
Official sources
Last verified 29 October 2026 against the sources above.
Questions about Bayesian Health
Does Medical AI have to explain how it reaches its outputs?
Not always in a technical sense, but transparency about the product is increasingly expected. Many machine learning models cannot give a simple step-by-step reason for each output, so regulators focus on clear information for users: intended use, inputs, how the model was developed and tested, performance, and known limitations.
In the US, one of the criteria for clinical decision support to fall outside device regulation is that a healthcare professional can independently review the basis for its recommendations. FDA has also published transparency principles for machine learning devices with Health Canada and MHRA.
For buyers, a vendor's ability to document how its model works and where it fails is often more useful than heat maps or confidence scores alone.
What is automation bias, and why does it matter for clinical AI?
Automation bias is the tendency of people to over-rely on a suggestion from an automated system, either following an incorrect output or missing something because the system did not flag it.
FDA's Clinical Decision Support Software guidance (issued January 2026) discusses automation bias and notes it increases in urgent situations where there is not enough time to consider other information. This is one reason FDA does not consider software intended for critical, time-sensitive decisions to meet the criteria for non-device CDS.
Organizations reduce automation bias through user training, clear display of the basis and limits of an output, workflows that keep independent clinical review, and monitoring of how the tool is actually used.
What is clinical decision support (CDS) software?
Clinical decision support software provides clinicians with patient-specific information, alerts or recommendations to help with prevention, diagnosis or treatment decisions. Examples include drug-interaction alerts, guideline reminders, risk scores and AI-generated predictions.
CDS can be rule-based or use machine learning, and it is usually delivered inside the EHR. Not all CDS is a medical device. In the US, software that meets all four criteria in section 520(o)(1)(E) of the FD&C Act is excluded from the device definition, as explained in FDA's Clinical Decision Support Software guidance (current version issued January 2026). CDS that analyzes images or signals, or is meant to replace clinician judgment, generally remains a device.
Find vendors under Diagnostic Decision Support in the Medical AI directory.